Loading...

Alarming Lapses in Inspection of Drugs Made in Foreign Countries

March 10, 2021 by Tom Ramstack
Alarming Lapses in Inspection of Drugs Made in Foreign Countries
GAO Health Care Director Mary Denigan-Macauley, PhD.

WASHINGTON — A government report released Tuesday raised alarms about the quality of pharmaceuticals made in foreign countries but consumed by Americans.

It said the purity of the drugs is questionable because of a lack of adequate inspections by the Food and Drug Administration of the manufacturing plants that produce them.

“The outbreak of COVID-19 has called greater attention to the United States’ reliance on foreign drug manufacturers,” the Government Accountability Office report said. “FDA reports that 74% of establishments manufacturing active ingredients and 54% of establishments manufacturing finished drugs for the U.S. market were located overseas, as of May 2020.”

The report did not describe specific drugs that are contaminated but merely said there is potential for them to slip into U.S. markets because of scant oversight of the manufacturing processes.

The Food and Drug Administration reported doing 1,671 inspections of foreign and domestic drug manufacturing facilities in 2019.

By January of this year, “we found that the total number of FDA inspections of foreign establishments was about 60% lower in fiscal year 2020 than during each of the previous two fiscal years,” the GAO report said. “From March 2020 … through the end of the fiscal year, FDA conducted three foreign mission critical inspections—one each in Canada, Germany, and India.”

Last March, the Food and Drug Administration announced it would temporarily halt all but critical inspections to protect its employees from COVID-19.

The sharp drop in mandatory inspections has delayed new drug applications. Critics of the agency argue that Food and Drug Administration inspectors should be considered essential workers required to continue with their normal job duties.

The warnings about inspection lapses were the subject of a House Appropriations subcommittee hearing Tuesday, where lawmakers sought assurances drugs used by Americans are safe.

“The health, safety and welfare of the American people are at great peril,” said Rep. Sanford Bishop, D-Ga., who chairs the subcommittee on agriculture, rural development, Food and Drug Administration and related agencies.

He cited government reports showing that in 2016, about 1,000 of 3,000 foreign drug manufacturers had never been inspected by the Food and Drug Administration, particularly in India. Some of them lacked proper sterilization of equipment and engaged in deceit to hide their lack of professional standards, Bishop said.

He put part of the blame on different inspection procedures the FDA uses for foreign facilities.

In the United States, the inspectors usually show up unannounced to check on manufacturers’ compliance with safety standards. In foreign countries, they lack discretion for unannounced inspections.

“The majority of foreign plants receive notice of inspections as much as 12 weeks in advance,” Bishop said.

As a result, they often clean up their plants before inspectors arrive to create the appearance of health and safety compliance, he said.

Mary Denigan-Macauley, director of health care for the Government Accountability Office, blamed a lack of qualified personnel for some shortcomings in inspections.

“Something isn’t quite working and that’s what we’re trying to figure out,” Denigan-Macauley told lawmakers. “There are still vacancies year after year.”

In addition, the Food and Drug Administration lacks interpreters who understand the languages of foreign manufacturers. Denigan-Macauley said inspectors often must depend on the drug manufacturers to offer them translation services.

“If you’re relying on that establishment for the translations, that’s not acceptable,” she said.

Rep. Jeff Fortenberry, R-Neb., questioned the wisdom of allowing Chinese manufacturers to determine the quality of drugs sold in America after their government initially concealed the source and dangers of COVID-19.

“I am not very optimistic” about whether China would ensure the quality of drugs sold in the United States, he said.

He recommended that the Food and Drug Administration use its authority more often to stop foreign-made drugs of questionable quality from entering the United States.

“It’s a powerful tool and I hope it’s used well,” Fortenberry said.

In The News

Health

Voting

Prescription Drugs

April 27, 2022
by Tom Ramstack
Lawmakers Say Consulting Firm Marketing Contributed to Half-Million Opioid Deaths

WASHINGTON — A congressional panel cast suspicions on a global business consulting firm Wednesday as a potential villain in the... Read More

WASHINGTON — A congressional panel cast suspicions on a global business consulting firm Wednesday as a potential villain in the opioid epidemic that has killed more than a half-million Americans. A McKinsey & Co. official admitted to earning at least $86 million for helping pharmaceutical companies... Read More

April 19, 2022
by Dan McCue
Supreme Court Seeks Solicitor General Input on Biologic Drug Patents

WASHINGTON — The U.S. Supreme Court on Monday asked Solicitor General Elizabeth Prelogar to weigh in on a drug patent... Read More

WASHINGTON — The U.S. Supreme Court on Monday asked Solicitor General Elizabeth Prelogar to weigh in on a drug patent case the outcome of which could ultimately be worth billions of dollars. The case, Amgen v. Sanofi, emanates from the U.S. District Court for the Federal... Read More

House Passes $35-a-Month Insulin Cap as Dems Seek Wider Bill

WASHINGTON (AP) — The House has passed a bill capping the monthly cost of insulin at $35 for insured patients,... Read More

WASHINGTON (AP) — The House has passed a bill capping the monthly cost of insulin at $35 for insured patients, part of an election-year push by Democrats for price curbs on prescription drugs at a time of rising inflation. Experts say the legislation, which passed 232-193... Read More

March 30, 2022
by Dan McCue
House to Vote on Insulin Price Reduction Bill Thursday

WASHINGTON — The House on Thursday is expected to vote to cap the out-of-pocket cost of insulin for consumers at... Read More

WASHINGTON — The House on Thursday is expected to vote to cap the out-of-pocket cost of insulin for consumers at $35 per month. If also passed by the Senate, which is expected to vote the measure up by Easter, the long-awaited reform will go into effect... Read More

March 19, 2022
by TWN
Congressional Panel Takes Deep Dive Into Future of FDA’s Accelerated Approvals

WASHINGTON — The House Energy and Commerce Subcommittee on Health panel Thursday spent the majority of their time considering the... Read More

WASHINGTON — The House Energy and Commerce Subcommittee on Health panel Thursday spent the majority of their time considering the future of the Food and Drug Administration's so-called Accelerated Approval Program. A number of the 20 different health care-related bills discussed by the subcommittee figure in... Read More

March 19, 2022
by TWN
CMS Decision to Limit Coverage of Alzheimer’s Treatment Takes Center Stage

WASHINGTON — A House panel scheduled to kick the tires on roughly 20 different health care-related bills on Thursday spent... Read More

WASHINGTON — A House panel scheduled to kick the tires on roughly 20 different health care-related bills on Thursday spent time considering the Food and Drug Administration’s decision to grant accelerated approval to the first disease-modifying treatment for Alzheimer’s disease and the Centers for Medicare and... Read More

News From The Well